Noxafil (Posaconazole)

Posaconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By blocking this pathway, the drug disrupts the fungal cell membrane, causing accumulation of toxic sterol intermediates and loss of membrane integrity, which halts fungal growth.

The prescribed dose of Noxafil is determined by the treating physician based on the specific indication, severity of infection, patient weight, organ function, and potential drug interactions. Dosage regimens are individualized and should follow the prescriber's instructions.

Posaconazole is classified as pregnancy category C. It should be avoided during pregnancy and lactation unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception while on therapy.

To request Noxafil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with older azoles such as fluconazole or itraconazole, posaconazole offers a broader spectrum of activity against molds like Aspergillus and some resistant Candida species. It also has a higher barrier to resistance but may have more drug‑interaction potential due to strong CYP3A4 inhibition.

Noxafil tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect the product from excess moisture, direct sunlight, and heat to maintain stability throughout its shelf life.

Noxafil is administered orally as a tablet. It can be taken with or without food, although a high‑fat meal may increase absorption. Patients should follow the prescribing clinician’s instructions regarding timing and any required dose adjustments.

The most serious adverse events linked to Noxafil include severe hepatic injury or failure, QT interval prolongation that can lead to cardiac arrhythmias, and rare but potentially life‑threatening hypersensitivity reactions such as anaphylaxis. Prompt medical attention is required if these occur.

Noxafil should not be used by individuals with known hypersensitivity to posaconazole or any azole antifungal. Patients with severe hepatic impairment, uncontrolled QT prolongation, or those taking contraindicated medications such as strong CYP3A4 inducers should avoid therapy unless alternative options are unavailable.